$-0.21 EPS Expected for Hydrogenics (HYG), Gemphire Therapeutics (GEMP) Shorts Increased By 12.14%

July 27, 2017 - By Henry Gaston

Analysts expect Hydrogenics Corporation (TSE:HYG) to report $-0.21 EPS on August, 2.They anticipate $0.11 EPS change or 34.38% from last quarter’s $-0.32 EPS. After having $-0.24 EPS previously, Hydrogenics Corporation’s analysts see -12.50% EPS growth. The stock increased 1.99% or $0.22 on July 26, reaching $11.28. About 6,733 shares traded. Hydrogenics Corporation (TSE:HYG) has 0.00% since July 27, 2016 and is . It has underperformed by 16.70% the S&P500.

Gemphire Therapeutics Incorporated (NASDAQ:GEMP) had an increase of 12.14% in short interest. GEMP’s SI was 227,200 shares in July as released by FINRA. Its up 12.14% from 202,600 shares previously. With 30,500 avg volume, 7 days are for Gemphire Therapeutics Incorporated (NASDAQ:GEMP)’s short sellers to cover GEMP’s short positions. The SI to Gemphire Therapeutics Incorporated’s float is 6.29%. The stock increased 4.22% or $0.79 during the last trading session, reaching $19.49. About shares traded. Gemphire Therapeutics Inc (NASDAQ:GEMP) has 0.00% since July 27, 2016 and is . It has underperformed by 16.70% the S&P500.

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $204.19 million. The Firm is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It currently has negative earnings. It is developing its product candidate, gemcabene , which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

Among 3 analysts covering Gemphire Therapeutics (NASDAQ:GEMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Gemphire Therapeutics had 3 analyst reports since August 30, 2016 according to SRatingsIntel. The rating was initiated by Jefferies on Tuesday, August 30 with “Buy”. The firm has “Outperform” rating by RBC Capital Markets given on Tuesday, August 30. The firm earned “Buy” rating on Tuesday, August 30 by Canaccord Genuity.

Hydrogenics Corp is a Canada-based firm, which creates and makes hydrogen generation products based on water electrolysis technology, and fuel cell products based on proton exchange membrane technology. The company has market cap of $139.77 million. The Company’s divisions are Onsite Generation and Power Systems. It currently has negative earnings. The OnSite Generation segment is based in Oevel, Belgium and develops products for industrial gas, hydrogen fueling and renewable energy storage markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com